| Literature DB >> 31394842 |
Eleni Fitsiou1,2, Aglaia Pappa3.
Abstract
Aromatic plants have a long and significant history in the traditional medicine of many countries. Nowadays, there is an increasing interest in investigating the biological properties of aromatic plant extracts mainly due to their diversity, high availability, and low toxicity. Greece is abundant in aromatic plants, which can be attributed to the country's geographical position, the morphology of its landscape, and its numerous mountainous and insular areas. In the past 15 years, a number of aromatic plant extracts of Greek origin have been studied for their bioactivities, including their antiproliferative potential against different types of cancer. Although the pharmacological activities of specific species of Greek origin have been reviewed before, no gathered information on explicitly Greek species exist. In this review, we summarize existing data on the antiproliferative activity of extracts isolated from Greek aromatic plants and discuss their molecular mode(s) of action, where available, in order to identify promising extracts for future research and link chemical constituents responsible for their activity. We conclude that essentials oils are the most frequently studied plant extracts exhibiting high diversity in their composition and anticancer potential, but also other extracts appear to be worthy of further investigation for cancer chemoprevention.Entities:
Keywords: Greece; antiproliferative activity; aromatic plants; cancer; natural extracts
Year: 2019 PMID: 31394842 PMCID: PMC6720353 DOI: 10.3390/antiox8080290
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Figure 1(a) The percentage of plant families of the species studied for their antiproliferative activity. (b) The percentage of studies on aromatic plant extracts performed in (i) in vitro models, (ii) in vitro and in vivo models, or (iii) only in in vivo models.
Summary of the antiproliferative activity of extracts isolated from Greek aromatic plants. The cell lines are human unless otherwise stated. N.d. = not determined. (−) in major component and collection location columns indicates that the authors report no data on the major components and collection location, respectively. (--) in dose/concentration column indicates that the concentrations used were not reported.
| Family | Species | Extract | Major Components | Collection Location | Type of Cell | Dose/ | Effect | Ref. |
|---|---|---|---|---|---|---|---|---|
| Anacard-iaceae | Essential oil | α-Pinene (67.71%) Myrcene (18.81%) | Commercial | Colon carcinomas Caco2 and HT-29 | 0.000445–0.89 mg/mL | Caco2 EC50 48 h = 0.0368 ± 0.0225 mg/mL | [ | |
| Colon cancer mouse model (in vivo) | 0.58 g/kg b.w. | 44–52% tumor volume inhibition | ||||||
| Essential oil | α-Pinene (72.93%) Myrcene (13.57%) | Commercial | Ovarian adenocarcinoma 2008 | -- | EC50 > 500 μg/mL | [ | ||
| Essential oil | − | Commercial | chronic myelogenous leukemia K562 | 0.01–0.1% | K562: Reduction of viability. Induction of apoptosis; Reduction of VEGF release levels; Inhibition of endothelial cells proliferation and neovascularization; | [ | ||
| Essential oil | α-Pinene (~70%) | Commercial | Mouse Lewis lung carcinoma | 0.01–0.02% | Cell proliferation suppression; VEGF release reduction; Chemokine release reduction; GTPases Ras, RhoA and NF- | [ | ||
| Lung cancer mouse model (in vivo) | 45 mg/Kg b.w. | Tumor growth suppression; Apoptosis induction; Neovascularization reduction; Chemokine expression reduction GTPases, Ras, RhoA and NF- | ||||||
| Essential oil | − | − | Mouse Lewis lung carcinoma | 0.01% | PTEN, E2F7, HMOX1 increase; NOD1 decrease; Apoptosis induction; Inflammation decrease | [ | ||
| Essential oil | − | Commercial | Mouse Lewis lung carcinoma | 0.01–0.04% | Reduction of MMP-2, ICAM-1 and VCAM-1 expression levels; attenuation of f-actin fiber formation; limitation of cell invasiveness; impairment of tumor cell adhesive interactions and neovascularization potential | [ | ||
| Mastic gum hexane extract | Caryophyllene | − | Colon carcinoma HCT116 | 25–100 µg/mL | Dose-dependent growth inhibition | [ | ||
| Mastic gum hexane extract | − | − | Colon cancer mouse model (in vivo) | 200 mg/Kg b.w. | Tumor growth suppression | [ | ||
| Mastic gum ethanol extract | − | − | Colon carcinoma HCT116 | 0.2–0.6% | Dose-dependent inhibition of cell growth | [ | ||
| Iridaceae | Ethanolic extract | trans-crocin 1 (56.4%) | Commercial (Association of Crocus Producers) | Rat glioma C6 | 0.5–10 mg/mL | EC50 = 3 mg/mL | [ | |
| Verbena-ceae |
| Essential oil | Neral ( | Athens | Hepatocellular carcinoma HepG2 | 0.64–920 µg/mL | HepG2 EC50 = 74 ± 2.8 μg/mL | [ |
| Rutaceae |
| Essential oil | Limonene (64.35%) | − | hepatocellular carcinoma HepG2 | 0.00063–0.9 mg/mL | HepG2: EC50 = 0.091 ± 0.012 mg/mL | [ |
|
| Essential oil | Limonene (93.78%) | Corfu Island | hepatocellular carcinoma HepG2 | 0.0006–0.86 mg/mL | HepG2 EC50 = | [ | |
| Apiaceae |
| Essential oil | − | 0.00068–0.97 mg/mL | HepG2 EC50 = 0.39 ± 0.0282 mg/mL | |||
| Lamiaceae |
| Essential oil | Carvone (85.41%) | − | 0.00067–0.96 mg/mL | HepG2 EC50 = 0.22 ± 0.038 mg/mL | ||
|
| Essential oil | Methyl chavicol (74.92%) | − | 0.00068–0.98 mg/mL | HepG2 EC50 = 0.18 ± 0.028 mg/mL | |||
| Ethanolic extract | Rosmarinic and caffeic acid | Ioannina | cervix adenocarcinoma HeLa | 12.5–200 μg/mL | HeLa: EC50 = 164.61 ± 2.58 μg/mL | [ | ||
| Essential oil | Eugenol, Isoeugenol, Linalool | Donation from greenhouse | HeLa: EC50=86.11±0.82 μg/mL | |||||
| Methanolic extract | Mainly Phenylethanoid glycosides and flavonoids | Thessalia | Breast adenocarcinoma | 50–750 μg/mL | MCF-7: EC50 = 417.53 ± 53.4 μg/mL | [ | ||
| Essential oil | Carvacrol (33.72%) | Mt Parnon, Peloponnese | Breast adenocarcinoma | 0.00000025–0.25% | EC50 = 0.08 ± 0.03% | [ | ||
|
| Carvacrol (39.1%) | Mt Immitos, Attiki | EC50 = 0.002 ± 0.00038% | |||||
| Essential oil | Carvacrol (79.58%) | Euboea | Larynx carcinoma | -- | Complete cell death in all cell lines at 0.0001% | [ | ||
| Essential oil | Carvacrol (48%) | Northern Greece | Hepatocellular carcinoma HepG2 | 0.0000589–0.842 mg/mL | EC50 48 h | [ | ||
| Colon cancer mouse model (in vivo) | 0.370 g/kg b.w | 52% lower mean tumor volume | ||||||
| Hyperi-caceae | Essential oil | Carvacrol (52.18%) | Crete | Hepatocellular carcinoma HepG2 | 0.00007–0.1% | EC50 = 0.0069 ± 0.00014% | [ | |
| Essential oil | Crete | Colon carcinoma LoVo | 2.5–100 µg/mL | LoVo: EC50 24 h = 84.76 ± 1.03 μg/mL | [ | |||
| Dichloromethane residue | Ursolic acid | Crete | Mouse leukemia P-388 | -- | P-388: EC50 = 8 μg/mL | [ | ||
| Ethanolic extract | − | Almost inactive | ||||||
| Infusion | Carvacrol 3745.3 | Crete | Colon carcinoma HT-29 | 0.2, 0.6, 1 μg/μL | PC3 antiproliferative activity: | [ | ||
| Rosmarinic acid 669 | ||||||||
| Carvacrol 182,138 | ||||||||
| Rosmarinic acid 9674.4 | ||||||||
| Rosmarinic acid 8082.7 | ||||||||
| Epicatechin 29,275.4 | Central | |||||||
| Methanolic extract | Hypericin | Wild collected 38/15, 41/15: North-West Macedonia 43/15: North–Central Macedonia | Colon adenocarcinoma | 0.01–100 μg/mL | 38/15 & 41/15: Did not affect cell viability | [ | ||
| Cultivated NAT, D-4: North Greece | NAT: Reduced viability to 41.14% only at the highest concentration | |||||||
| Aqueous solution (AS) | − | Ioannina | Urinary bladder carcinoma T24 | AS and MS: 0.63-20 μL/mL | T24:AS EC50 = 4.7 μL/mL | [ | ||
| Methanolic solution (MS) | − | |||||||
| Methanolic extract (ME) | Hyperforin (7.62%) | |||||||
| Petroleum ether extract (PEE) | Hyperforin (18.9%) | |||||||
| Methanolic extract | − | Monodendrι, Epirus | Colon carcinoma Caco2 | 10–100 mg/mL | EC50 of all extracts against all cell cancer lines > 100 mg/mL, apart from: | [ | ||
| − | Mt. Parnitha, Attiki | |||||||
| − | Mt. Parnassos, Viotia | |||||||
| − | Korinthos | |||||||
| − | Rafina, Attiki | |||||||
| Lamiaceae |
| Essential oil | Spathulenol (9%) | Karpathos Island | Lung carcinoma COR-L23 | 5–200 μg/mL | COR-L23: EC50 = 80.7 ± 2.1μg/mL | [ |
|
| Essential oil | caryophyllene (12.2%) | Pelion mountain | COR-L23: EC50 = 104 ± 2.1 μg/mL | ||||
| Essential oil | Carvacrol (13.9%) | Karpathos Island | COR-L23: EC50 = 143 ± 2.1 μg/mL | |||||
| Essential oil | Carvacrol (10.1%), caryophyllene (9.8%) | Crete | COR-L23: EC50 = 104 ± 2.1 μg/mL | |||||
| Asteraceae | infusion | Carvacrol 9321.5 | Crete | Colon carcinoma | 0.2, 0.6, 1 μg/μL | HT-29: Pink savory most effective, chamomile least cytotoxic | [ | |
| Lamiaceae |
| Carvacrol 23,274 | ||||||
| Carvacrol 1220 | ||||||||
|
| Carvacrol 177,855 | |||||||
| Carvacrol 87,814 | ||||||||
| Carvacrol 3755 | ||||||||
| - | Lesvos Island | Breast adenocarcinoma MCF-7 | 10–100 μg/mL | EC50 of all extracts against all cell | [ | |||
| Methanolic extract | - | Mt Parnassos, Viotia | ||||||
| - | Mt. Parnitha, Attiki | |||||||
| - | Mt Parnassos, Viotia | |||||||
| - | Zante Island | |||||||
| - | Mt. Penteli, Attiki | |||||||
| - | Mt. Parnitha, Attiki | |||||||
| - | Lesvos Island | |||||||
| - | Mt. Parnitha, Attiki | |||||||
| - | Mt. Pateras, Attiki | |||||||
| - | Mt.- Pateras, Attiki | |||||||
| - | Mt.Hymettus, Attiki | |||||||
| - | Mt. Parnitha, Attiki | |||||||
| - | Trikala | |||||||
| - | Mt. Kitheron, Attiki | |||||||
| - | Samos Island | |||||||
| - | Domokos, Fthiotida | |||||||
| - | Mt. Parnitha, Attiki | |||||||
| - | Lesvos Island | |||||||